Jefferies Financial Group Inc. Has $28.33 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Jefferies Financial Group Inc. increased its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 167.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,216,954 shares of the company’s stock after acquiring an additional 762,147 shares during the period. Jefferies Financial Group Inc. owned about 2.37% of Spyre Therapeutics worth $28,331,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in SYRE. Barclays PLC boosted its stake in Spyre Therapeutics by 64.7% in the third quarter. Barclays PLC now owns 105,467 shares of the company’s stock valued at $3,101,000 after buying an additional 41,424 shares in the last quarter. Franklin Resources Inc. lifted its stake in Spyre Therapeutics by 2.5% in the 3rd quarter. Franklin Resources Inc. now owns 760,666 shares of the company’s stock valued at $23,322,000 after purchasing an additional 18,762 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Spyre Therapeutics by 29.4% in the third quarter. JPMorgan Chase & Co. now owns 29,473 shares of the company’s stock valued at $867,000 after buying an additional 6,701 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Spyre Therapeutics during the fourth quarter worth $290,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Spyre Therapeutics in the 4th quarter valued at $46,000. 80.39% of the stock is owned by institutional investors.

Spyre Therapeutics Price Performance

Shares of Spyre Therapeutics stock opened at $14.10 on Friday. The stock’s 50-day moving average is $15.37 and its 200 day moving average is $22.05. Spyre Therapeutics, Inc. has a one year low of $10.91 and a one year high of $40.49. The firm has a market cap of $849.89 million, a price-to-earnings ratio of -1.89 and a beta of 2.78.

Spyre Therapeutics (NASDAQ:SYRE) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.74) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.02. On average, sell-side analysts expect that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. The Goldman Sachs Group upgraded Spyre Therapeutics to a “strong-buy” rating in a report on Tuesday, February 18th. Leerink Partnrs upgraded shares of Spyre Therapeutics to a “strong-buy” rating in a research report on Tuesday, April 8th. Wolfe Research assumed coverage on shares of Spyre Therapeutics in a report on Tuesday, March 18th. They set an “outperform” rating and a $27.00 price target on the stock. Wedbush restated an “outperform” rating and issued a $65.00 price objective on shares of Spyre Therapeutics in a report on Monday, May 5th. Finally, Leerink Partners assumed coverage on Spyre Therapeutics in a report on Tuesday, April 8th. They set an “outperform” rating and a $45.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $51.17.

Spyre Therapeutics Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).